CEO, Co-founder, and Chairman of the Board of Directors

Dr. Linke, CEO and co-founder of SiVEC Biotechnologies, has secured $8 million in financing and non-dilutive funding, boasts 15+ years of R&D experience in biotherapeutics and drug delivery, and is a first named inventor on 35 patents related to SiVEC’s technology. Dr. Linke holds a Ph.D. in Infectious Disease Epidemiology and a Master's in Biomedical Engineering from Colorado State University. Dr. Linke has been recognized as an Inspiring Female Founder, a former US Olympic Swimming Trials qualifier and nine-time US Master's National Swimming Champion. In addition to serving as Chairman of the Board at SiVEC Biotechnologies, I am a Member of the Board at the Colorado Bioscience Association. Under her leadership, SiVEC has earned prestigious accolades, including being named the 2022 Top Emerging Company at BIO International.

VP of Operations, Co-founder

Ms. Mora is Co-Founder and Vice President of Operations at SiVEC Biotechnologies, where she leads company operations and plays a key role in advancing the development of SiVEC’s proprietary platform technologies. She brings over 14 years of experience spanning infectious disease research, vaccine development, and translational R&D. She's inventor on 35 patents related to SiVEC’s technology. Prior to her work at SiVEC, Darcy led the development of more than ten wildlife vaccines for the United States Department of Agriculture and has contributed to building and scaling early-stage biotechnology programs. At SiVEC, Darcy oversees a broad range of functions including operational strategy, team development, grant funding, and coordination of preclinical studies. Her expertise spans molecular and cellular biology, assay development, vaccine formulation, and in vivo research models, enabling her to bridge scientific execution with operational leadership in a fast-paced startup environment. Darcy holds a Master’s degree in Veterinary Epidemiology and a Bachelor’s degree in Biochemistry from Colorado State University.

Director of Research & Development

As Director of R&D at SiVEC, Dr. Williams leads scientific strategy and research execution across the company’s platform and pipeline. He brings more than 15+ years of experience in molecular biology and Escherichia coli genetics, with additional expertise in molecular genetics, eukaryotic cell biology, host-pathogen interactions, inflammatory biology, and oncology. He is a named inventor on several patent applications directed at expanding the capabilities of the SiVEC delivery platform for targeted delivery of nucleic acid therapies, gene editing therapies, polypeptides and antibodies, cancer therapeutics, and vaccines. Outcomes from this work have been published in Engineering in Life Sciences and were also featured in the June 2025 edition of Nature BioPharma Dealmakers. Prior to joining SiVEC, Dr. Williams studied aging and age-related disease at the CECAD Research Center at the University of Cologne in Germany. He holds degrees from Indiana University, including a Ph.D. in Microbiology, and completed postdoctoral fellowships at Harvard University and the University of Southern California.

Scientist

Dr. Groseclose has an expertise spanning synthetic biology, bacterial engineering, protein engineering, biochemistry, and high-throughput screen development, with over 9 years of experience working in academic, government, and corporate R&D labs. He received his Ph.D. in Chemical and Biomolecular Engineering from Georgia Institute of Technology and was a Director’s Postdoctoral Fellow in the Biochemistry and Biotechnology Group at Los Alamos National Laboratory before joining SiVEC.

Scientist

Dr. Hammerstrom received her PhD in Medical Microbiology and Immunology from Creighton University, followed by postdoctoral training at the University of Massachusetts Amherst and Colorado State University. Her background spans protein misfolding diseases, neuroinflammatory pathways, preclinical animal models, and disease pathogenesis, with additional expertise in protein biochemistry, protein engineering, and high-throughput assay development. At SiVEC, she helps advance next-generation therapeutic delivery through the BactPac platform, translating complex biology into impactful therapies.

Scientist

Darrian Newman is a Colorado native with BS and Thesis MS degrees in Chemical Engineering from the Colorado School of Mines, where he focused on Biological Engineering and minored in Biomedical Engineering. His background spans engineering, molecular biology, and computational biology, including work using CRISPR and metabolic modeling to engineer cyanobacteria for biofuel production and developing microalgae strains for Sustainable Aviation Fuel at scale. At SiVEC, he brings a strong ability to integrate complex ideas into practical solutions that support innovation at the forefront of science and medicine.

Board Member

With over 25 years in global Pharma, including a 9-year tenure at Boehringer Mannheim/Roche, Ms. Hauser excels in corporate business development, fundraising, strategic planning, and international commercialization. Notably, she has focused on capital access and fundraising specialized in cell- and gene therapy technologies and precision medicine. As the former Executive Director, Innovation & Entrepreneurship at California Life Sciences, she focused on seed and series A capital raising. Additionally, she initiated and chaired the Women In Bio-Entrepreneur Center, connecting over 90 female founders with life sciences technologies across the US. She is a member of the Investment Committee of the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus.

Board Member

Dr. Sherris brings over 30 years of expertise in translational medicine, from basic research, pharmaceutics, and diagnostics. As a successful serial entrepreneur, he has built biotechnology companies from scratch, shaping strategy, implementing programs, and navigating funding and acquisitions. Dr. Sherris, a hands-on CEO, entrepreneur, and scientist, actively collaborates with venture capital firms, investment banks, and angel investors. His experience includes managing both external and internal research and development for pharmaceutical and biotech companies. A respected speaker at biopharmaceutical conferences, published author, and holder of patents across therapeutic areas, Dr. Sherris has held key roles in public and private companies, overseeing drug development, fostering partnerships, and raising capital.

Board Member

Richard Freed serves on the Board of Directors, where he provides strategic guidance on corporate development, partnerships, and the advancement of SiVEC’s platform and therapeutic programs. Richard brings experience in biotechnology innovation, venture creation, and strategic transactions. During his more than decade-long tenure at DuPont, he led multiple biotech venture launches, advised on healthcare strategy, and oversaw mergers and acquisitions. Notably, he served as Venture Manager for one of the largest joint ventures in DuPont’s Industrial Biosciences portfolio, a $200M+ partnership with BP focused on developing gene-edited yeast to produce isobutanol as a next-generation biofuel. He has deep expertise in CRISPR cell and gene therapy and translational biotechnology. His experience bridging platform technologies with commercial execution provides valuable insight as SiVEC advances both its internal pipeline and external partnerships.

Scientific Advisory Board

Dr. Wyckoff, an Immunologist with 33 years of research experience, has past positions in R&D leadership at major global companies, including Merial, Boehringer Ingelheim, and Elanco. Most recently, he was the Director of BioMARC, a biopharmaceutical CDMO. Dr. Wyckoff serves as a Scientific Advisor to SiVEC Biotechnologies, offering expertise in scale-up and production of biologics and biotherapeutics, process development and analytical evaluation, study design, licensing, regulatory readiness, and partnerships.

Scientific Advisory Board

Dr. Hagen Richter is a leading expert in microbial genetics, CRISPR/Cas technology, and RNA biology, with a distinguished career in nucleic acids research and biomanufacturing. As Head of Nucleic Acids Research at Wacker, he drives advancements in genetic and RNA-based technologies. He holds a Ph.D. in Molecular Biology and a Master of Science in Biotechnology, with a prestigious Postdoctoral Fellowship under Nobel Laureate Prof. Dr. Emmanuelle Charpentier at the Max Planck Institute. Dr. Richter provides specialized guidance to SiVEC in LBP manufacturing and microbial production of CRISPR/Cas systems, mRNA, and other macromolecules, ensuring scalability and precision in SiVEC’s platform technologies. His expertise bridges molecular innovation and large-scale biomanufacturing, positioning SiVEC for success in next-generation therapeutics.

Scientific Advisory Board

Dr. Zahra Kabiri is a leading expert in RAS biology and cancer signaling, with a distinguished track record in modeling RAS-dependent tumorigenesis and identifying novel regulators of oncogenic pathways. As Assistant Professor of Surgery and Pathology at Duke University School of Medicine and a member of the Duke Cancer Institute, her research focuses on how signaling dynamics shape cancer progression in KRAS-mutant tumors. Dr. Kabiri holds an M.D. from Isfahan University, an M.S. in pathology from the National University of Singapore, and a Ph.D. in biochemistry from Duke-NUS Graduate Medical School and completed a prestigious research fellowship at pharmacology and cancer biology at Duke University. Her insights into translational control and molecular oncology are helping to define new therapeutic strategies for hard-to-treat cancers, and her expertise is instrumental in guiding SiVEC’s oncology programs.